Grufity logoGrufity logo
StocksFundsSearch Filings

Alnylam Pharmaceuticals Inc Stock Research

ALNY

188.26USD+2.26(+1.22%)Market Closed

Market Summary

USD188.26+2.26
Market Closed
1.22%

ALNY Alerts

ALNY Stock Price

ALNY RSI Chart

ALNY Valuation

Market Cap

23.4B

Price/Earnings (Trailing)

-21.96

Price/Sales (Trailing)

22.55

EV/EBITDA

-26.16

Price/Free Cashflow

-38.68

ALNY Price/Sales (Trailing)

ALNY Profitability

EBT Margin

-108.63%

Return on Equity

714.91%

Return on Assets

-31.9%

Free Cashflow Yield

-2.59%

ALNY Fundamentals

ALNY Revenue

Revenue (TTM)

1.0B

Revenue Y/Y

29.59%

Revenue Q/Q

26.76%

ALNY Earnings

Earnings (TTM)

-1.1B

Earnings Y/Y

27.56%

Earnings Q/Q

16.09%

Price Action

52 Week Range

120.43242.97
(Low)(High)

Last 7 days

-1.3%

Last 30 days

-4.7%

Last 90 days

-0.8%

Trailing 12 Months

49.9%

ALNY Financial Health

Current Ratio

3.51

Debt/Equity

-10.02

Debt/Cashflow

-0.83

ALNY Investor Care

Shares Dilution (1Y)

2.91%

Diluted EPS (TTM)

-8.69

Peers (Alternatives to Alnylam Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
322.8B
1.6B
-3.71% 80.48%
-168.39
207.32
77.54% 1.62%
285.4B
56.7B
-14.98% -6.85%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-6.81% 6.09%
20.2
7.2
-25.07% -47.28%
85.0B
9.2B
2.07% 22.38%
26.07
9.23
15.86% 32.99%
23.4B
1.0B
-4.69% 49.89%
-21.96
22.55
22.88% -19.27%
11.8B
975.7M
3.71% 78.87%
-10.59
12.11
27.41% -212.78%
9.7B
2.0B
-8.21% -7.77%
13.31
4.89
12.05% 52.86%
MID-CAP
5.2B
504.0K
-7.29% 316.43%
-16.55
2.5K
-66.53% -27.52%
3.5B
363.3M
17.72% 8.70%
-4.94
9.63
3.39% -55.81%
3.5B
204.6M
17.81% 4.32%
-6
17.05
-7.52% 10.65%
2.2B
18.9M
-10.74% -34.21%
-3.03
118.36
- -16.17%
SMALL-CAP
3.5B
-
0.59% -4.18%
-8.22
37.46
34.30% -67.22%
1.2B
256.5M
-28.21% 63.82%
12.26
4.75
66.85% 120.61%
315.4M
165.3M
-25.22% 48.69%
-3.45
1.91
130.70% 57.97%
41.8M
881.7K
29.00% 3203.36%
-0.83
19.11
-77.61% -29.84%

Financials for Alnylam Pharmaceuticals

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue8.0%1,037,418,000960,918,000884,245,000879,980,000844,287,000
  S&GA Expenses3.2%770,658,000746,696,000652,912,000628,251,000-
  R&D Expenses3.9%883,015,000850,026,000799,227,000776,150,000-
EBITDA5.1%-926,557,000-975,871,000-773,788,000-694,931,000-
EBITDA Margin12.1%-0.89-1.02-0.88-0.79-
Earnings Before Taxes4.5%-1,126,993,000-1,180,274,000-978,567,000-892,225,000-
EBT Margin11.6%-1.09-1.23-1.11-1.01-
Interest Expenses-4.2%155,968,000162,871,000162,061,000152,868,000-
Net Income4.3%-1,131,156,000-1,182,123,000-980,717,000-892,874,000-
Net Income Margin11.4%-1.09-1.23-1.11-1.01-
Free Cahsflow2.9%-613,333,000-631,747,000-660,051,000-654,279,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-4.4%3,3923,5463,5353,3303,434
  Current Assets-5.6%2,5412,6922,6912,4722,590
    Cash Equivalents-22.4%6728661,073576534
  Inventory2.3%13212911589.0079.00
  Net PPE-0.1%523523515508504
Liabilities-1.4%3,6513,7053,6033,1543,032
  Current Liabilities-12.3%673768773658606
  Long Term Debt0.1%678677---
Shareholder's Equity-63.8%-259-158176401-
  Retained Earnings-2.7%-6,743-6,569-6,361-5,955-5,678
  Additional Paid-In Capital1.0%6,5226,4556,3376,1736,117
Shares Outstanding0.3%124124123121121
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations0.9%-536-541-559-578-577
  Share Based Compensation4.6%241231232138139
Cashflow From Investing42.0%241169-104-506-492
Cashflow From Financing2.7%4374266559311,231

Risks for ALNY

What is the probability of a big loss on ALNY?

100%


Probability that Alnylam Pharmaceuticals stock will be more than 20% underwater in next one year

43.5%


Probability that Alnylam Pharmaceuticals stock will be more than 30% underwater in next one year.

18.5%


Probability that Alnylam Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ALNY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Alnylam Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for ALNY

Cumulative Returns on ALNY

20.2%


10-Year Cumulative Returns

15.8%


7-Year Cumulative Returns

13.5%


5-Year Cumulative Returns

11.3%


3-Year Cumulative Returns

What are the long-term rolling returns for ALNY?

FIve years rolling returns for Alnylam Pharmaceuticals.

Annualized Returns

Which funds bought or sold ALNY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Front Row Advisors LLC
new
-
3,000
3,000
-%
2023-05-23
Toroso Investments, LLC
added
77.84
506,000
1,520,000
0.03%
2023-05-22
AMERIPRISE FINANCIAL INC
added
328
29,440,000
40,699,000
0.01%
2023-05-18
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
added
22.63
314,888
9,333,050
2.60%
2023-05-18
CENTAURUS FINANCIAL, INC.
added
1.48
-25,000
151,000
0.01%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-4.27
-7,099,000
29,665,000
0.04%
2023-05-18
JPMORGAN CHASE & CO
reduced
-1.05
-123,361,000
619,936,000
0.08%
2023-05-17
Sunbelt Securities, Inc.
new
-
3,512
3,512
-%
2023-05-17
Thrivent Financial for Lutherans
unchanged
-
-39,000
210,000
-%
2023-05-17
Advisory Services Network, LLC
reduced
-66.99
-141,848
54,688
-%

1–10 of 41

Latest Funds Activity

Are funds buying ALNY calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ALNY
No. of Funds

Alnylam Pharmaceuticals News

MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by ....
MarketBeat,
2 hours ago
Morningstar
7 Undervalued Biotech Stocks.
Morningstar,
2 days ago
Investor's Business Daily

Schedule 13G FIlings of Alnylam Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
3.3%
4,074,144
SC 13G/A
Feb 13, 2023
capital world investors
13.5%
16,593,958
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.35%
11,507,116
SC 13G/A
Feb 06, 2023
wellington management group llp
5.09%
6,261,642
SC 13G/A
Jan 31, 2023
blackrock inc.
7.0%
8,665,702
SC 13G/A
Jan 19, 2023
baillie gifford & co
7.65%
9,407,871
SC 13G/A
Sep 09, 2022
capital world investors
10.7%
12,816,777
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
5.4%
6,535,368
SC 13G
Feb 09, 2022
vanguard group inc
8.95%
10,702,771
SC 13G/A

ALNY Fair Value

Recent SEC filings of Alnylam Pharmaceuticals

View All Filings
Date Filed Form Type Document
May 23, 2023
8-K
Current Report
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading

Latest Insider Trading transactions for ALNY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-04-28
Garg Pushkal
sold
-488,595
199
-2,455
cmo & evp dev & med affairs
2023-04-27
Tanguler Tolga
sold
-287,215
194
-1,476
evp, chief commercial officer
2023-04-27
Vaishnaw Akshay
sold
-465,464
194
-2,392
president
2023-04-27
Greenstreet Yvonne
sold
-1,481,810
194
-7,615
chief executive officer
2023-04-27
Garg Pushkal
sold
-357,855
194
-1,839
cmo & evp dev & med affairs
2023-04-27
Poulton Jeffrey V.
sold
-190,113
194
-977
evp, chief financial officer
2023-04-26
Poulton Jeffrey V.
acquired
-
-
3,277
evp, chief financial officer
2023-04-26
Tanguler Tolga
acquired
-
-
3,277
evp, chief commercial officer
2023-04-26
Garg Pushkal
acquired
-
-
4,294
cmo & evp dev & med affairs
2023-04-26
Vaishnaw Akshay
acquired
-
-
5,312
president

1–10 of 50

Yvonne L. Greenstreet
1660
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Total revenues$ 319,290$ 213,259
Operating costs and expenses:  
Cost of goods sold41,43223,457
Cost of collaborations and royalties13,43712,170
Research and development230,569169,893
Selling, general and administrative183,659154,471
Total operating costs and expenses469,097359,991
Loss from operations(149,807)(146,732)
Other (expense) income:  
Interest expense(28,955)(42,362)
Interest income18,6551,012
Other expense, net(12,255)(51,274)
Total other expense, net(22,555)(92,624)
Loss before income taxes(172,362)(239,356)
Provision for income taxes(1,739)(985)
Net loss$ (174,101)$ (240,341)
Net loss per common share - basic (in dollars per share)$ (1.40)$ (2.00)
Net loss per common share - diluted (in dollars per share)$ (1.40)$ (2.00)
Weighted-average common shares used to compute basic net loss per common share (in shares)124,111120,393
Weighted-average common shares used to compute diluted net loss per common share (in shares)124,111120,393
Statements of Comprehensive Loss  
Net loss$ (174,101)$ (240,341)
Other comprehensive income (loss):  
Unrealized gain (loss) on marketable securities4,125(7,217)
Foreign currency translation gain1,4102,376
Defined benefit pension plans, net of tax(5)35
Total other comprehensive income (loss)5,530(4,806)
Comprehensive loss(168,571)(245,147)
Net product revenues  
Revenues:  
Total revenues276,328186,872
Net revenues from collaborations  
Revenues:  
Total revenues36,46225,945
Royalty revenue  
Revenues:  
Total revenues$ 6,500$ 442

ALNY Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 672,245$ 866,394
Marketable debt securities1,372,5741,297,890
Marketable equity securities25,85628,122
Accounts receivable, net219,434237,963
Inventory131,879128,962
Prepaid expenses and other current assets119,030132,916
Total current assets2,541,0182,692,247
Property, plant and equipment, net523,032523,494
Operating lease right-of-use assets215,049215,136
Restricted investments49,38849,390
Other assets63,45366,092
Total assets3,391,9403,546,359
Current liabilities:  
Accounts payable62,23798,094
Accrued expenses508,599545,460
Operating lease liability43,05541,967
Deferred revenue35,79442,105
Liability related to the sale of future royalties23,70640,289
Total current liabilities673,391767,915
Operating lease liability, net of current portion259,399261,339
Deferred revenue, net of current portion191,257193,791
Convertible debt1,017,8871,016,942
Liability related to the sale of future royalties, net of current portion1,285,2001,252,015
Other liabilities224,046212,580
Total liabilities3,651,1803,704,582
Commitments and contingencies (Note 13)
Stockholders’ deficit:  
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 202200
Common stock, $0.01 par value per share, 250,000 shares authorized; 124,241 shares issued and outstanding as of March 31, 2023; 123,925 shares issued and outstanding as of December 31, 20221,2431,240
Additional paid-in capital6,522,0916,454,540
Accumulated other comprehensive loss(39,124)(44,654)
Accumulated deficit(6,743,450)(6,569,349)
Total stockholders’ deficit(259,240)(158,223)
Total liabilities and stockholders’ deficit$ 3,391,940$ 3,546,359